Analysts and Calls -- UBS Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and Calls -- UBS

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who started this subject	2/5/2003 2:37:19 PM
From: tuck	Read Replies (1) of 19

Posted for the name of another analyst on the team: >>NEW YORK, Feb 5 (Reuters) - UBS Warburg on Wednesday said analyst Jeff Cianci cut his price target for drug development company Diversa Corp. (NasdaqNM:DVSA - News) to $12 from $15 because of increased expenses, particularly in research and development. Shares of Diversa closed at $7.63 on the Nasdaq Stock Market on Tuesday.<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next